IDEAYA Biosciences (IDYA) Revenue & Revenue Breakdown
IDEAYA Biosciences Revenue Highlights
Latest Revenue (Y)
$23.39M
Main Segment (Y)
Methionine Adenosyl Transferase2 A Program Supply
IDEAYA Biosciences Revenue by Period
IDEAYA Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $23.39M | -54.08% |
| 2022-12-31 | $50.93M | 82.28% |
| 2021-12-31 | $27.94M | 43.01% |
| 2020-12-31 | $19.54M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
IDEAYA Biosciences generated $23.39M in revenue during NA 2023, up -54.08% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
IDEAYA Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $3.92M | -51.19% |
| 2023-09-30 | $8.04M | 126.81% |
| 2023-06-30 | $3.54M | -55.03% |
| 2023-03-31 | $7.88M | 95.92% |
| 2022-12-31 | $4.02M | -86.46% |
| 2022-09-30 | $29.70M | 407.59% |
| 2022-06-30 | $5.85M | -48.49% |
| 2022-03-31 | $11.36M | 283.36% |
| 2021-12-31 | $2.96M | -66.99% |
| 2021-09-30 | $8.98M | 2.51% |
| 2021-06-30 | $8.76M | 20.82% |
| 2021-03-31 | $7.25M | -31.44% |
| 2020-12-31 | $10.57M | 17.89% |
| 2020-09-30 | $8.97M | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
IDEAYA Biosciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
IDEAYA Biosciences Revenue Breakdown
IDEAYA Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|
| Methionine Adenosyl Transferase2 A Program Supply | $2.40M | $2.41M | $2.35M |
| Methionine Adenosyl Transferase2 A Program Research And Development | - | $9.49M | $16.14M |
| Polymerase Theta Program Research And Development Service | - | $13.75M | $25.78M |
| The Option | - | $17.68M | $17.23M |
| Werner Helicase Program Research And Development Service | - | $20.83M | $27.79M |
IDEAYA Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 22: Methionine Adenosyl Transferase2 A Program Supply (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|
| Werner Helicase Program Research And Development Service | $1.44M | $2.82M | $6.25M | $16.06M | $18.16M | $19.09M | $22.39M | $23.78M | $25.69M |
| Polymerase Theta Program Research And Development Service | - | - | - | $2.12M | $10.00M | $11.27M | $12.76M | $17.32M | $22.39M |
| Methionine Adenosyl Transferase 2 A Option Member | - | - | - | - | $17.47M | $17.49M | - | - | - |
| Methionine Adenosyl Transferase2 A Program Research And Development | - | - | - | - | - | $3.78M | $10.29M | $13.02M | $14.77M |
| The Option | - | - | - | - | - | - | $17.37M | $17.32M | $17.31M |
| Methionine Adenosyl Transferase2 A Program Supply | - | - | - | - | - | - | $2.37M | $2.36M | $2.36M |
IDEAYA Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 23: Werner Helicase Program Research And Development Service (100.00%).
IDEAYA Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| VECT | VectivBio | $27.34M | $676.00K |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| SWTX | SpringWorks Therapeutics | $5.45M | $21.01M |
| FIXX | Q32 Bio | $1.16M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| VRNA | Verona Pharma | - | - |
| CERE | Cerevel Therapeutics | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| TERN | Terns Pharmaceuticals | - | - |
| VTYX | Ventyx Biosciences | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |
IDYA Revenue FAQ
What is IDEAYA Biosciences’s yearly revenue?
IDEAYA Biosciences's yearly revenue for 2023 was $23.38M, representing a decrease of -54.08% compared to 2022. The company's yearly revenue for 2022 was $50.93M, representing an increase of 82.28% compared to 2021. IDYA's yearly revenue for 2021 was $27.94M, representing an increase of 43.01% compared to 2020.
What is IDEAYA Biosciences’s quarterly revenue?
IDEAYA Biosciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). IDYA's quarterly revenue for Q4 2023 was $3.92M, a -51.19% decrease from the previous quarter (Q3 2023), and a -2.46% decrease year-over-year (Q4 2022).
What is IDEAYA Biosciences’s revenue growth rate?
IDEAYA Biosciences's revenue growth rate for the last 3 years (2021-2023) was -16.31%, and for the last 5 years (2019-2023) was 0%.
What are IDEAYA Biosciences’s revenue streams?
IDEAYA Biosciences's revenue streams in c 22 are Methionine Adenosyl Transferase2 A Program Supply
What is IDEAYA Biosciences’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of IDEAYA Biosciences was Methionine Adenosyl Transferase2 A Program Supply. This segment made a revenue of $2.4M, representing 100.00% of the company's total revenue.